


PHARMACEUTICAL 2019



Homology Medicines Inc. Rank 90 of 371





PHARMACEUTICAL 2019





Homology Medicines Inc. Rank 90 of 371

The relative strengths and weaknesses of Homology Medicines Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Homology Medicines Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 145% points. The greatest weakness of Homology Medicines Inc. is the variable Revenues, reducing the Economic Capital Ratio by 38% points.

The company's Economic Capital Ratio, given in the ranking table, is -11%, being 320% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	221,685
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	25,433
Liabilities, Non-Current	0
Other Assets	1,772
Other Compr. Net Income	-4.0
Other Expenses	0
Other Liabilities	38,944
Other Net Income	4,349
Property and Equipment	35,637
Research and Development	47,948
Revenues	3,684
Selling, General and Administrative Expense	17,300

Output Variable	Value in 1000 USD
Assets	259,094
Liabilities	64,377
Expenses	65,248
Stockholders Equity	194,717
Net Income	-57,215
Comprehensive Net Income	-57,217
Economic Capital Ratio	-11%